Eye to Brain Connection

Exclusion Criteria

• •1. Any ophthalmologic condition that would prevent obtaining retinal imaging and/or could interfere with the analysis of the MHRC-C1 images by the CAS, including:
• •* Pupil dilation contraindicated (due to a pathology, or presence of 3 quadrants with Van Herick frading of 0 or 1 without iridotomy)
• •* Inadequate pupil dilatation (\< 6mm diameter) preventing uniform illumination of the retina with the MHRC-C1
• •* Diagnosis of glaucoma or signs of glaucoma (excavation ratio ≥0.7)
• •* Signs of vascular occlusion or retinopathy (microaneurysm, exudate, hemorrhage or edema) within a diameter of 10 mm from the mid-point between the optic nerve head and the macula
• •* Presence of drusen and/or age-related macular degeneration (AREDS 9-step scale
• •* 4 - cumulative drusen area diameter ≥ 250 um, pigmentary changes and cumulative drusen area diameter ≥ 63 um or pigmentary changes and cumulative geographic atrophy area diameter ≥ 354 um)
• •* Macular anomaly (e.g. macular hole, dystrophy, degeneration)
• •* Nuclear sclerosis \> 2 (LOCS II four-point grading system) or presence of central cortical or central posterior subcapsular cataract
• •* Deficient visual fixation (inability to fixate for at least 2 s)
• •* Refractive error outside the range of -15 D to +15 D
• •* Corneal or media opacities (e.g. Weiss ring) affecting retinal imaging on a cumulative area \> 1 disc area within a diameter of 10 mm from the mid-point between the optic nerve head and the macula (i.e. the area of interest for the MHRC-C1 imaging)
• •* Scar, atrophy, naevus, tumor, epiretinal membrane or retinal pucker with a cumulative area \> 1 disc area within a diameter of 10 mm from the mid-point between the optic nerve head and the macula
• •* Papilledema
• •2. Inability of obtaining at least 3 images of satisfactory quality with the MHRC-C1 per the Optina Diagnostics quality index software.
• •3. Impossibility of obtaining a satisfactory quality amyloid-PET scan for interpretation by imaging specialists.
• •4. Individuals currently enrolled in cerebral amyloid modifying medication studies.